- The Copenhagen facility will add a 6Pack™ suite with six 2000L bioreactors.
- The new suites will be operational by November 2018.
- The expansion includes capabilities for harvesting, purification, and media production.
- The facility will support high antibody titer processes.
Expansion Overview
AGC Biologics is increasing manufacturing capacity at its Copenhagen, Denmark facility as part of its global expansion strategy. The facility will add a Single-use Bioreactor (SUB) 6Pack™ suite, which includes six 2000L production bioreactors and a 2000L seed train.
New Capabilities
This proprietary bioreactor configuration will enable flexible, innovative, and customized cGMP production capabilities, offering scales from 2000L to 12000L within a single run. The bioreactors can operate in single unit operations or in groups, either simultaneously, sequentially, or staggered, to meet specific production needs.
Additional Enhancements
The expansion also includes new capabilities for harvesting, purification, buffer, and media production. These enhancements will support the processing of various therapeutic proteins, including high antibody titer processes.
Timeline
The new suites are scheduled to be operational by November 2018 and are expected to support the manufacturing of several commercial products.
